Premium
SENP2 suppresses epithelial‐mesenchymal transition of bladder cancer cells through deSUMOylation of TGF‐βRI
Author(s) -
Tan Mingyue,
Zhang Dingguo,
Zhang Encheng,
Xu Dongliang,
Liu Zhihong,
Qiu Jianxin,
Fan Yu,
Shen Bing
Publication year - 2017
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.22687
Subject(s) - epithelial–mesenchymal transition , biology , cancer research , metastasis , transforming growth factor , gene knockdown , bladder cancer , cancer , cancer cell , tumor progression , signal transduction , microbiology and biotechnology , cell culture , genetics
SUMO‐specific protease 2 (SENP2) is a deSUMOylation protease that plays an important role in the regulation of transforming growth factor‐β (TGF‐β) signaling. Aberrant TGF‐β signaling is common in human cancers and contributes to tumor metastasis by inducing an epithelial‐mesenchymal transition (EMT). In previous studies, we demonstrated that SENP2 suppresses bladder cancer cell migration and invasion. However, little is known about whether SENP2 inhibits EMT by regulating TGF‐β signaling in bladder cancer progression. Here, we investigated the role of SENP2 in regulating TGF‐β signaling and bladder cancer metastasis in vitro and in vivo. We found that SENP2 is frequently downregulated in bladder cancer, especially in metastatic bladder cancer. SENP2 downregulation is associated with more aggressive phenotypes and poor patient outcomes. SENP2 knockdown results in a decrease of E‐cadherin and an increase of N‐cadherin and fibronectin at both transcript and protein levels, indicating that SENP2 negatively regulates EMT. On the contrary, SENP2 overexpression suppresses TGF‐β signaling and TGF‐β‐induced EMT. We further demonstrated that SENP2 regulates TGF‐β signaling partly through deSUMOylation of TGFβ receptor I (TGF‐βRI). Functionally, SENP2 suppresses bladder cancer cell invasion in vitro and tumor metastasis in vivo, acts as a tumor suppressor gene in bladder cancer. Our results establish a function of SENP2 in metastatic progression and suggest its candidacy as a new prognostic biomarker and target for clinical management of bladder cancer.